ArticleClinical pharmacokinetics2023

Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies.

Laiyi Chua et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.